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Parathyroid Glands and 
Hyperparathyroidism: A General 
Overview
Andre Luis Maion Casarim
Abstract
Hyperparathyroidism (HPT) is a clinical condition caused by the increase of 
parathyroid hormone (PTH) synthesis by the parathyroid glands. PTH has a central 
and fundamental role in the control of calcium and phosphorus homeostasis. Its 
action on the kidney, bone, and, indirectly, intestinal cells implies a rapid increase 
in extracellular calcium flow. This clinical condition may be due to an intrinsic 
parathyroid disorder or secondary to an imbalance of calcium metabolism in 
patients with systemic diseases, such as chronic renal failure. The treatment of 
hyperparathyroidism may be clinical, with the control of calcium, phosphorus, and 
PTH levels, or surgical, depending on the various forms presented. The purpose of 
the chapter is to discuss the types of hyperparathyroidism, their relationship with 
phosphorus and mainly calcium metabolism, as well as the main forms of diagnosis 
and treatment.
Keywords: hyperparathyroidism, calcium, bone diseases, kidney diseases, 
parathyroid hormone
1. Introduction
Hyperparathyroidism (HPT) is a pathology caused by the increased synthesis 
of parathyroid hormone (PTH) by the parathyroid glands. This process can be a 
consequence of an intrinsic parathyroid disorder or secondary to an imbalance 
of calcium metabolism in patients with systemic diseases, such as chronic kidney 
disease (CKD) [1]. PTH plays a central and fundamental role in homeostasis of the 
control of calcium and phosphorus in the body. Its action on the renal, bone, and, 
indirectly, intestinal cells implies a rapid increase in the extracellular flow of cal-
cium. This hormone has a short half-life (2–3 min) that quickly mobilizes calcium 
to the intravascular. It binds to specific membrane receptors on the kidney and bone 
cells, fibroblasts, chondrocytes, vascular smooth muscle, adipocytes, and placental 
trophoblasts [2].
2. History
The parathyroid glands were initially discovered in the eighteenth century by 
Richard Owen, who dissected the parathyroid glands of an approximately 2260 kg 
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rhino, being reported as “a small, compact yellow glandular body attached to 
the thyroid at the point where the veins emerge” [3, 4]. However, the definitive 
discovery of the parathyroid glands in humans was made in 1877 by Swede Ivar 
Sandström, a medical student at Uppsala University, Sweden, publishing his work 
in which he wrote: “Almost three years ago I found on the thyroid gland of a dog a 
small organ, hardly as big as a hemp seed, which was enclosed in the same connec-
tive tissue as the thyroid, but could be distinguished therefrom by the light color. 
Microscopically the examination revealed glandular tissue completely different 
from that of the thyroid” [4]. After identification in dogs, he finally dissected such 
structures in human cadavers, calling them glandulae parathyroidae (Figure 1).
Later, in 1891, Eugene Gley reported symptoms of tetany when these glands 
were removed during thyroidectomies [5]. At the beginning of the twentieth 
century, the theory described by Jacob Erdheim emerged, which related hypertro-
phy of parathyroid tissue as a response to bone disease (osteomalacia and/or cystic 
fibrous osteitis). This theory was rejected by Felix Mandl in 1925, who performed 
the first parathyroid surgery in Vienna. Initially, it was believed that bone lesions 
were a consequence of a parathyroid deficiency, and to prove it, transplantation of 
cadaveric parathyroid tissues was performed in patients with cystic bone lesions 
and hypercalciuria. With the procedure unsuccessful, Mandl proceeded with cervi-
cal exploration and identified a 21 × 12 × 12 mm parathyroid “tumor,” which was 
resected, observing the patient’s improvement [6]. Still in 1925, Collip brought a 
breakthrough in studying the function of PTH, by treating patients with tetany due 
to parathyroidectomy with relative PTH extract with relative success [4].
The term tertiary HPT came up with Dr. Walter St. Goar, when describing a case 
report in the New England Journal of Medicine, number 268, in 1963, of a patient 
with CKD and functional parathyroid autonomy [7]. McPhaul, in 1964, published 
Figure 1. 
Original drawing by Ivar Sandström of human parathyroid glandular anatomy [4].
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the first surgical success in patients with this clinical condition [8]. Later, in 1968, 
Davies and colleagues also studied 200 cases of HPT and, of these, obtained 14 
cases of tertiary HPT [7].
3. Physiology
PTH plays a central and fundamental role in homeostasis of the control of 
calcium and phosphorus in the body. It is produced by the parathyroid glands, 
composed mainly of main cells, and, to a lesser extent, by oxyphil cells [1, 4]. Studies 
show that, over time, the main cells are replaced by oxyphil cells, which are more 
sensitive to PTH production, especially in cases of CKD [9, 10]. Its action on renal, 
bone, and, indirectly, intestinal cells implies a rapid increase in the extracellular flow 
of calcium (Figure 2). This hormone is a peptide with 84 amino acids and a molecu-
lar weight of 9500 Da. It has a short half-life (2–3 min) and is broken down into the 
amino-terminal and carboxy-terminal portions. Only the amino-terminal portion 
has biological effects on the body, while the carboxy-terminal portion remains inac-
tive. PTH binds to specific membrane receptors in renal and bone cells, fibroblasts, 
chondrocytes, vascular smooth muscle, adipocytes, and placental trophoblasts [11].
3.1 Effect of PTH on the kidneys
PTH causes an increase in the calcium reabsorption of the glomerular filtrate. 
This is mainly due to some factors. First, it acts in the loop of Henle, increasing 
the voltage gradient to allow the passive transport of ionized calcium. Then, it acts 
on the granular portion of the distal contorted tubules, inducing translocation of 
preformed calcium channels on the cell surface, increasing the entry of calcium 
into the vascular lumen. Finally, it also acts on the collecting tubules by changing 
the activation of the Na+/Ca2+ pump [11–13]. In addition, PTH has other effects on 
kidney cells, such as an increase in phosphate excretion, with increased phospha-
turia and decreased serum phosphate; increased bicarbonate clearance with urine 
Figure 2. 
Mechanisms of action of parathyroid hormone.
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alkalinization, resulting from decreased bicarbonate reabsorption in the proximal 
renal tubules; inhibition of sodium reabsorption in the proximal tubules, with 
increased clearance of free water and greater urinary flow; and increased activity 
of vitamin D1 alpha-hydroxylase, with greater production of the active form of 
vitamin D (calcitriol) [12, 14, 15].
3.2 Effect of PTH on bones
PTH produces both anabolic and catabolic effects, depending on the phases of 
action. In the early phase, there is a mobilization of calcium from the bones, enter-
ing equilibrium with the extracellular fluids. In the late phase, there is an increase 
in the synthesis of bone enzymes, such as lysosomal enzymes, which promotes 
bone resorption and remodeling. PTH also inhibits osteoclasts and stimulates 
bone resorption, leading to an increase in serum alkaline phosphatase and urinary 
hydroxyproline (markers of osteolysis) [11–13].
3.3 Effect of PTH on the intestine
PTH has no direct action on the intestine. Its effect is due to an increase in the 
synthesis of calcitriol (activate form of vitamin D) in the kidneys, through the 
stimulation of the enzyme α1-hydroxylase. Calcitriol has an effect on increasing 
serum calcium from the resorption of bowel lumen [11].
4. Embryology and anatomy of the parathyroid glands
Embryologically, the parathyroid glands have an endodermal origin, usually 
four glands, and rarely may be in number of three, five, or more glands. They 
develop through the proliferation of the dorsal part of the branchial pharyngeal 
pouches. Both parathyroid glands migrate to the posterior portion of the thyroid 
gland, since the lower ones are able to migrate to the thymus or upper mediasti-
num [4, 12, 16].
4.1 Inferior parathyroid glands
The inferior parathyroid glands originate from the dorsal portion of the third 
branchial pouch. This branchial pouch differs around the 5th to the 6th week of 
gestation, when the ventral portion gives rise to the thymus. Around the 7th week 
of pregnancy, both the thymus and the lower parathyroid loosen the connection 
with the pharynx, occurring medial and caudal migration of the thymus, bring-
ing together the inferior parathyroid, when, finally, it separates from the thymus. 
Usually the inferior parathyroid glands are found outside the capsule of the thyroid 
gland and have a more variable location [17]. Caudal migration close to the thymus 
explains the lower localization of the inferior parathyroid glands (derived from 
the third branchial pouch) than the superior parathyroid glands (derived from the 
fourth branchial pouch). During this process, debris from the parathyroid tissue 
that can form supernumerary glands may detach. The arterial supply of the inferior 
parathyroid glands is from the branches of the inferior thyroid artery [17–19].
4.2 Superior parathyroid glands
The superior parathyroid glands originate from the dorsal portion of the fourth 
branchial pouch. In the 7th week of pregnancy, they lose their relationship with the 
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pharynx and adhere to the thyroid gland, which is migrating caudally and medi-
ally. This migration occurs to a lesser extent than the migration of the thymus and 
inferior parathyroid glands, and therefore their locations are more predictable. 
Superior parathyroid glands are usually located more posteriorly and medially than 
inferior parathyroid glands, often located on the dorsal surface and outside the 
thyroid capsule [4, 17–19].
These glands are closely related to the inferior thyroid artery and its intersec-
tion with the recurrent laryngeal nerve, although many anatomical variations may 
occur. The superior parathyroid glands have arterial supply from the branches of 
the inferior thyroid artery and posterior branches of the superior thyroid artery. 
The inferior thyroid artery generates branches to supply the parathyroid glands 
before irrigating the thyroid lobes.
Parathyroid appears in the body as two superior and two inferior glands in 
approximately 85–90% of the population. In addition, in 10% of the population, 
they appear as supernumerary, with 5 or more glands, with reports of up to 10 
parathyroid glands in a single patient [19].
Figure 3 shows the locations of the parathyroid glands.
5. Clinical presentations
HPT can be divided into primary, secondary, or tertiary.
5.1 Primary HPT
PTH, in these cases, is produced through a stimulus of the parathyroid due to 
an intrinsic pathology of this gland. In 85% of the cases, a parathyroid adenoma 
forms, generating an increase in PTH production. However, hyperplasia of the 
Figure 3. 
Anatomical location of the parathyroid glands, posterior view (modified by F. netter, atlas of human 
anatomy).
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parathyroid gland (13%) or carcinoma (1%) can occur. Parathyroid adenoma is 
the most common clinical presentation in primary HPT. It usually presents with 
only one adenoma, but it can manifest in more than one parathyroid, known as 
multiple adenomas [20–22]. Structural genetic mutations are associated with the 
etiology of the adenoma, although it can also occur after exposure to neck irradia-
tion, treatment with lithium, or thiazide diuretics [20, 23]. The consequence is the 
disorderly overproduction of PTH, increasing osteoclastic activity and therefore 
raising calcium levels in the body. PTH also stimulates renal calcium reabsorption 
and acts on the activation of vitamin D, increasing intestinal calcium absorption. 
Most are asymptomatic; however the patient may develop clinical manifestations. 
The most frequent consequence of primary HPT is nephrolithiasis that develops 
in almost 15–20% of cases. Nevertheless, HPT is found in just 5% of patients with 
nephrolithiasis. Osteoporosis, fibrous osteitis, and peptic disease may be also 
found in these patients. Neuropsychiatric and neuromuscular disorders such as 
asthenia, weakness, and mild depression can be found less frequently [24]. In rare 
presentations, brown tumors may be formed, the etiology of which is associated 
with the disruption of bone turnover between osteoblastic and osteoclastic activity, 
resulting in benign bone tumors. Sporadic presentation is more frequent; however, 
family forms may be associated. The main familial manifestations are multiple 
endocrine neoplasia (MEN) type I, or Werner’s syndrome (HPT, pancreatic tumor 
and pituitary tumor), and type IIA, or Sipple’s syndrome (HPT, medullary thyroid 
carcinoma and pheochromocytoma), and are associated with the expression of the 
RET proto-oncogene [24, 25].
Other existing familial forms described are primary neonatal HPT, familial hypo-
calciuric hypercalcemia, jaw tumor HPT syndrome, and isolated familial HPT [26]. 
Associated with primary HPT is the parathyroid carcinoma, a rare presentation, less 
than 1% of cases. It is suspected when there are high levels of serum calcium and 
PTH and may also have a palpable cervical mass on the thyroid gland topography. 
HPT in patients, if not treated quickly and efficiently, can progress rapidly to com-
plications secondary to hypercalcemia and may progress to death [20, 26, 27].
5.2 Secondary HPT
Secondary HPT, unlike primary HPT, is a systemic and non-intrinsic pathology 
of the parathyroid gland, the consequence of which affects the functioning and 
metabolism of the parathyroid glands. It is the result of a parathyroid response to a 
tendency of hypocalcemia in order to maintain calcium homeostasis. It occurs due 
to low calcium absorption and vitamin D deficiency. Hypovitaminosis D is the main 
cause of secondary HPT in developed countries, in which confinement and low 
sun exposure occur frequently. As a result, there is a decrease in intestinal calcium 
absorption and a tendency towards serum hypocalcemia. The feedback mechanism 
stimulates the parathyroid glands and increases PTH synthesis, mobilizing calcium 
from the bones to maintain intravascular calcium homeostasis. Another important 
cause of secondary HPT is CKD, in which the kidney injury generates low calcium 
reabsorption in the distal renal tubules with consequent hypocalcemia. It is also 
in the kidney that the conversion of vitamin D (cholecalciferol) to its active form 
(calcitriol) occurs through the enzyme alpha1-hydroxylase. In CKD, this conversion 
is impaired and shows a consequent decrease in serum calcitriol rates and intestinal 
calcium absorption. As a result, there is an increase in PTH production and osteo-
clastic activity to try to normalize serum calcium levels. In advanced cases, there is 
intense damage to bone health, with osteoporosis, severe bone pain, fibrous osteitis, 
and even pathological fractures [16, 28, 29]. At the same time, renal injury causes 
phosphate retention, with an increase in serum inorganic phosphate.
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The chronic renal patient with secondary HPT frequently presents with major 
bone disease, bone pain, itching, cardiovascular disorders, and, in advanced cases, 
pathological bone fractures [28, 29].
5.3 Tertiary HPT
Tertiary HPT manifests itself through an evolution of secondary HPT. In these 
cases, the continuous stimulus to the overproduction of PTH leads the autonomy of 
the parathyroid glands to produce PTH in high amounts. In the case of CKD, many 
patients undergo kidney transplants, expecting normalization of calcium reabsorp-
tion, conversion of vitamin D to its active form (calcitriol), and a consequent drop 
in PTH levels and normalization of the calcium rates. However, autonomous para-
thyroid glands maintain PTH overproduction even with renal calcium reabsorption 
normalized. The main consequence is the increase of the calcium serum levels. Most 
patients are asymptomatic, although some maintained bone pain and risk of frac-
tures. In these cases, persistent hypercalcemia, chronic renal graft dysfunction, bone 
disease progression, cardiovascular events, and the risk of developing nephrolithia-
sis in the transplanted renal graft justify the early treatment of the disease [7, 30].
6. Diagnosis
In HPT, anamnesis and physical examination are of fundamental importance for 
accurate diagnosis.
Hypercalcemia is the main consequence of the primary HPT. In most cases, 
the disease is asymptomatic, occupying more than 80% of cases [21, 26, 31]. This 
condition was introduced after the 1970s, when routine laboratory tests began to 
be performed in asymptomatic patients [32]. However, they can develop symptoms 
that usually begin when calcium levels exceed 12 mg/dL and include manifestations 
in several systems. Neurological disorders manifest with changes in the level of 
consciousness, confusion, or lack of concentration. Gastrointestinal manifesta-
tions, such as nausea, epigastric pain due to peptic disease, or even pancreatitis, can 
be found. Nephrolithiasis can occur, mainly of repetition, polydipsia or polyuria. 
Bone pain and pathological fractures are also reported, in addition to brown tumors 
in the bone skeleton. Cardiovascular manifestations and heart rhythm disorders are 
also associated with hypercalcemia [33]. We can measure ionized serum calcium or 
total calcium. The total calcium measurement needs to be adjusted, because much 
of it is bonded with serum albumin. The formula can be shown in the following: 
corrected calcium = measured total serum calcium in mg/dL + 0.8 × (4.0 − patient’s 
serum albumin concentration in g/dL) [21]. Vitamin D participates actively in the 
diagnosis of primary HPT. The Institute of Medicine (IOM) affirms an evidence 
that the disease is more active when the vitamin D levels are below normal [21, 
34]. A variant of primary HPT is the normocalcemic HPT, when presents with 
levels of PTH above normal and normal levels of serum calcium. The evolution of 
these cases can be stable, without clinical complications or laboratory alterations, 
increase the serum calcium concentration, or cause bone, kidney, or cardiovascular 
impairments [35].
Secondary HPT caused by CKD normally courses with normal or low levels of 
serum calcium. Thus, the history of CKD, especially dialysis, is fundamental for 
the diagnostic interpretation. The symptoms are due to bone disease with bone 
pain that can be of different intensities and pathological fractures with difficulty in 
movement. The pruritus also is most frequent, especially when the phosphate levels 
Calcium Disorders, Hypercalcemia and Hypocalcemia - Recent Advances, New Perspectives...
8
Laboratory assessment of HPT is essential for diagnosis. Serum measurements 
of PTH, total serum calcium, ionized fraction of calcium, phosphorus, vitamin D, 
and alkaline phosphatase should be ordered. PTH will always be increased but to 
varying degrees. In primary HPT, PTH normally increases from two to four times 
normal, but it can reach much higher values  depending on the severity of the dis-
ease. Consequently, serum calcium also rises. Phosphorus levels are normal or low 
and alkaline phosphatase rises [33]. Very high levels of PTH and calcium raise the 
hypothesis of parathyroid carcinoma and require a different approach. In second-
ary HPT there is a high elevation of PTH, commonly reaching the values of 10–20 
times higher than normal or above in several cases. Calcium is usually in the normal 
range or at reduced levels, with hyperphosphatemia occurring in some cases. Due to 
decreased vitamin D activation in the kidney, there is a decrease in serum calcium 
due to low intestinal absorption.
In tertiary HPT, the parathyroid glands become autonomous in the production 
of PTH, despite the improvement in renal function, observed mainly in post-kidney 
transplant patients [36]. There is not a sufficient decrease in PTH, which remains in 
the range of 5–10 times greater than normal. Vitamin D levels also tend to normal-
ize, since the absence of kidney damage in the post-transplant patient normalizes 
the conversion of vitamin D into its active form (calcitriol) and also normalizes the 
intestinal absorption of calcium. Thus, the mechanisms lead to increased serum 
calcium concentration [36, 37].
Complementary imaging exams are of great value in therapeutic planning, 
especially when the surgical approach is programmed [38].
Cervical ultrasonography has an important value, i.e., in trying to locate the 
enlarged parathyroid glands, although there is difficulty due to the overlying 
position of the thyroid gland and the fact that it is operator dependent. Also, we 
need to study the thyroid anatomy and the possibility of thyroid nodules that can be 
approached at the same time, if surgery is performed [39, 40].
Computed tomography, as well as magnetic resonance imaging of the neck, can 
also help in locating the altered glands, especially if they are much larger than nor-
mal. One of the main exams is parathyroid scintigraphy, as it can functionally reveal 
parathyroid glands with increased activity through the uptake of 99Tc-sestamibi 
(MIBI) [38, 39]. Even more sensitive and specific than scintigraphy is SPECT/CT 
with MIBI. This examination has the same physiological foundations as flat scintig-
raphy; however its fusion with the computed tomography image allows for a much 
more precise location of the affected parathyroid glands.
Another resource is 4D computed tomography. The mechanism of realization 
of this exam is based on the arterial supply and venous drainage of the analyzed 
structure. It helps to differentiate a parathyroid gland from a lymph node or any 
other structure present in the neck or mediastinal region [38, 40, 41].
7. Treatment
The treatment for HPT may be with clinical management or surgery. However, 
there are other previous forms of disease control, mainly in primary asymptomatic 
HPT and secondary HPT in early stages. In asymptomatic cases of primary HPT, 
clinical follow-up without surgical treatment can be performed in most cases. 
However, in symptomatic cases with evidence of bone and kidney disease, surgical 
treatment is preferred [27, 31, 32, 42]. Treatment with bisphosphonates and calci-
mimetics, such as cinacalcete, is applied in cases of severe hypercalcemia and dif-
ficulty in performing surgical treatment in a timely manner [43, 44]. Therapeutic 
doubt arises in asymptomatic cases, in which initial surgical treatment is often not 
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indicated. According to the Fourth International Workshop, held in Italy in 2013 
[21], surgical indications in asymptomatic patients are reserved for the situations 
illustrated in Table 1.
The surgery performed on primary HPT is, in most cases, resection of the 
parathyroid affected by the adenoma (85% of cases). The use of intraoperative 
rapid PTH allows less chance of persistent disease (as in multiple adenomas) or 
future recurrences [26, 45–47]. In cases of parathyroid hyperplasia in primary HPT, 
as in multiple endocrine neoplasia, the surgical approach is the subject of much 
discussion. The possibility of subtotal/partial parathyroidectomy or total para-
thyroidectomy with autograft of fragments of parathyroid tissue in muscle tissue 
(forearm, presternal, or deltoid musculature) is described [25, 48]. Although rare, 
being responsible for less than 1% of cases of primary HPT, parathyroid carcinoma, 
when clinically suspected, should be treated with special care. Cases of severe 
hypercalcemia (greater than 14 mg/dL) and high levels of PTH (15–20 times higher 
than normal) should have parathyroid carcinoma as a diagnostic hypothesis. The 
recommended treatment is resection of the tumor en bloc with wide safety margins. 
The complete surgery includes partial thyroidectomy ipsilateral to the affected 
parathyroid, lymphadenectomy of the central compartment, and thymectomy [49].
In secondary HPT, initial clinical treatment is focused on the control of calcemia 
and phosphatemia and reduction of factors that stimulate PTH overproduction, as 
well as avoiding exposure to aluminum. Administration of vitamin D and calcium 
carbonate is used to try to correct serum calcium levels. Surgical treatment is 
usually indicated when intact PTH levels exceed 800 pg./mL, or when persistent 
symptoms such as bone fractures, pain refractory bone, intractable pruritus, 
brown tumor, and ectopic calcification. The pathology is systemic, and hyperplasia 
of all parathyroid glands occurs through feedback mechanisms. Therefore, the 
surgery to be performed can be the total parathyroidectomy with autograft of 
fragments of parathyroid tissue in the muscle tissue (forearm, presternal, or deltoid 
musculature) in order to avoid persistent hypoparathyroidism, or subtotal para-
thyroidectomy, with maintenance of parathyroid tissues to avoid persistent hypo-
parathyroidism [50–52]. The clinical management of secondary HPT is increasingly 
available, with acceptable responses, especially in patients who are not candidates 
for surgical treatment. Calcimimetics, such as cinacalcet, have acceptable results 
in reducing serum PTH and, mainly, improving the quality of life of chronic renal 
patients. Tolerability is reasonable, with some side effects, such as nausea, vomiting, 
and hypocalcemia, which may suspend treatment in some cases [53].
Indication of parathyroidectomy in asymptomatic primary HPT
1. Serum calcium 
values
Serum calcium 1.0 mg/dL (0.25 mmol/L) greater than the upper limit of normal
2. Imaging findings A.  Bone mineral density: T-score < −2.5 in the lumbar spine, hip, femur, or distal 
third of the radius
B. Vertebral fracture on X-ray, CT, MRI, or bone densitometry
3. Renal factors A. Creatinine clearance < 60 cc/min
B.  Calciuria 24 h > 400 mg/d (>10 mmol/dL) and increased risk of calculosis by 
biochemical analysis
C. Presence of nephrolithiasis or nephrocalcinosis by X-ray, ultrasound, or CT
4. Age <50 years
Table 1. 
Indication of parathyroidectomy in asymptomatic primary HPT [21].
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Tertiary HPT occurs in autonomy of parathyroid glands resulting from continu-
ous stimulation of PTH secretion, a consequence of secondary HPT. These cases are 
better demonstrated after kidney transplantation, when PTH levels are kept high 
even after treating the cause of secondary HPT, the renal disease. Surgical treat-
ment is indicated due to persistent hypercalcemia, in addition to symptoms that 
may be associated, such as bone pain, pathological fractures, and intractable pru-
ritus. The surgical approach, as in secondary HPT, can be total parathyroidectomy 
with autograft of parathyroid fragments in muscle tissue, or subtotal parathyroidec-
tomy [36, 54]. The measurement of intraoperative rapid PTH in cases of secondary 
and tertiary HPT during surgical treatment is the subject of much current discus-
sion, although it is increasingly accepted in order to avoid new approaches due to 
recurrent or persistent disease [36, 51, 55, 56].
8. Conclusion
Hyperparathyroidism is an important clinical condition with severe conse-
quences if it is not well diagnosed and treated. Knowledge of calcium metabolism 
is essential for the correct management of the patient with the disease. Primary 
hyperparathyroidism, although oligosymptomatic in most patients, should be 
viewed with magnitude by general practitioners with a basic health approach. The 
patient with hyperparathyroidism secondary to chronic kidney disease, often with 
several associated comorbidities, needs the best possible approach, directly influ-
encing his quality of life, improving cardiovascular and osteometabolic status.
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